Nanoinjection Platform for Drug Delivery in Breast Cancer Therapeutics

Conventional nanomaterial‐based drug delivery systems are often limited by rapid burst release, poor cellular uptake, drug degradation, and high local drug concentrations, reducing therapeutic efficacy. To address these challenges, a dual strategy is presented, integrating i) doxorubicin encapsulation within thermostable nanoarchaeosomes (NAs), derived from archaeal lipids, and ii) silicon nanotubes (SiNTs)‐based nanoinjection for intracellular delivery. This approach enables efficient transport of nanoarchaeosome‐loaded doxorubicin (NAD) into MCF‐7 breast cancer cells, inducing membrane perturbation and achieving controlled drug release over 700 h. NAD–SiNTs exhibit potent cytotoxicity, with an IC 5 ₀ of 60 n m, 23‐fold lower than free doxorubicin, while maintaining high biocompatibility in NIH‐3T3 fibroblasts. Fluorescence‐activated cell sorting (FACS) analysis revealed 44% necrosis in MCF‐7 cells post‐treatment with NAD–SiNTs. Moreover, chick embryo assays and angiogenesis gene expression studies confirm that NAD–SiNTs suppress tumor vasculature genes, effectively inhibiting angiogenesis. These findings position NAD–SiNTs as a promising drug delivery platform, enabling sustained and targeted breast cancer therapy.